Nevertheless, our findings suggest the possibility that a transient reduction in TDP-43 level by the ASO-mediated approach can lead to long-lasting therapeutic effects in patients with ALS/FTD. This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.